0.00Open0.05Pre Close0 Volume198 Open Interest0.50Strike Price0.00Turnover0.00%IV-92.20%PremiumMay 16, 2025Expiry Date6.56Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma141.10Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Seres Therapeutics Stock Discussion
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes. 85,742,623. 29,461,090 187,192. 0
Seres Therapeutics Inc - Ser-155 Receives Breakthrough Therapy and Fast Track Designations
Dow Jones· 3 mins ago
Seres' SER-155 Shows Breakthrough Results in Stem Cell Transplant Study, FDA Fast-Track Follows
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
Thursday, 9th January at 7:00 am
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to placebo; data support the broader potential of Seres' live ...
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)
No comment yet